Navigation Links
Vaccine shows promise in preventing mono
Date:12/10/2007

A new study suggests that a vaccine targeting Epstein-Barr virus (EBV) may prevent infectious mononucleosis, commonly known as mono or glandular fever. The study is published in the December 15 issue of The Journal of Infectious Diseases, now available online.

EBV is a member of the herpes virus family and one of the most common viruses in humans, with nearly all adults in developed countries such as the United States having been infected. EBV is often asymptomatic but commonly causes infectious mononucleosis, with 30 to 40 percent of adolescents who contract the virus developing the disease. EBV is also associated with a number of other diseases, some of the most serious being lymphomas and other lymphoproliferative diseases in people with compromised immune systems, such as transplant patients. Despite the frequency of EBV infections and infectious mononucleosis, the new study is the first to suggest the efficacy of a vaccine in preventing infectious mononucleosis.

The study was conducted by Etienne M. Sokal, MD, PhD, and colleagues at several Belgian institutions and pharmaceutical companies. The vaccine targets glycoprotein 350, a protein that facilitates the entry of EBV into immune system cells. In this preliminary, Phase II clinical trial, 181 young adults who had not previously been infected by EBV received three doses of either a placebo or the vaccine.

During the 18-month observation period, the proportion of symptomatic EBV infections was reduced from 10 percent (nine out of 91) in the control group to 2 percent (two out of 90) in the vaccinated group, indicating that those who did not receive the vaccine were almost 5 times more likely to develop infectious mononucleosis.

With these promising results in a small group of subjects, Dr. Sokal suggested the next step should be large-scale studies on the benefit in healthy subjects and ability to prevent acute EBV infection and post-transplant lymphoproliferative diseases in transplant patients. He added, There is currently no possibility to prevent or to treat acute mononucleosis, which has remained so far an unmet medical problem. This vaccine may decrease the socio-economic impact of acute mononucleosis.

Development of an EBV vaccine has had a slow and problematic history. These results suggest that the prevention of infectious mononucleosis is possible, and provide a framework for future trials looking to prevent more serious consequences of EBV infection.

In an accompanying editorial, Henry H. Balfour, Jr., MD, of the University of Minnesota Medical School, noted the importance of such studies on EBV vaccines, especially because the worldwide disease burden due to EBV is enormous. Balfour agreed that these findings should stimulate future research and larger clinical trials on the prevention and treatment of diseases associated with EBV.


'/>"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in ... quality care can be limited while the desire to conquer breakouts and eliminate skincare ... care for every customer online, today released its inaugural survey on the State of ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
(Date:3/28/2017)... Angeles, CA (PRWEB) , ... March 28, 2017 ... ... credential, which will be offered by the American Association of Integrative Medicine and ... presentations for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment ... City March 13-16, was a busy spot this year. Liz Solovay and Adrian ... for preventing outbreaks among camp communities during the upcoming 2017 camping season. “Lice ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: